US 7,388,072 B2
	MAGE peptides presented by HLA class II molecules
Yi Zhang, Brussels (Belgium); Pascal Chaux, Brussels (Belgium); Thierry Boon-Falleur, Brussels (Belgium); and Pierre Van Der Bruggen, Brussels (Belgium)
Assigned to Ludwig Institute for Cancer Research, New York, N.Y. (US)
Filed on May 23, 2003, as Appl. No. 10/444,683.
Application 10/444683 is a continuation in part of application No. 09/860840, filed on May 18, 2001, granted, now 7,049,413.
Prior Publication US 2004/0077045 A1, Apr. 22, 2004
Int. Cl. C07K 2/00 (2006.01); C07K 4/00 (2006.01); C07K 7/00 (2006.01); C07K 1/00 (2006.01); C07K 14/74 (2006.01)

U.S. Cl. 530—325  [530/326; 530/327; 530/328; 530/329; 530/402; 530/403]

21 Claims

1. An isolated MAGE HLA class II-binding peptide comprising SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, or SEQ ID NO:42 or consisting of SEQ ID NO:25, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:36, or SEQ ID NO:63, wherein the MAGE HLA class II-binding peptide does not include a full length MAGE protein.